Search research articles
Contact Us
Filters
Showing results (201-210 of 262) with videos related to
Page
of 27
Sort By:
Journal of Thoracic Disease
|
April 11, 2020
Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study
Wen Zhang, Yiping Zhang, Qiong Zhao, et al.
Cancer Immunology, Immunotherapy : CII
|
January 5, 2022
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial
Jifang Gong, Junning Cao, Qingyuan Zhang, et al.
Journal for Immunotherapy of Cancer
|
June 21, 2020
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
Lin Shen, Jun Guo, Qingyuan Zhang, et al.
Signal Transduction and Targeted Therapy
|
April 26, 2026
Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study
Lin Gui, Haifeng Liu, Huaqing Wang, et al.
Cancer Science
|
August 25, 2019
Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
Xiaoyun Zhou, Jiawei Shou, Jin Sheng, et al.
Advances in Therapy
|
March 2, 2025
First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study
Shukui Qin, Yuxian Bai, Jin Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 8, 2017
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study
Jianming Xu, Tae Won Kim, Lin Shen, et al.
Cancer Immunology, Immunotherapy : CII
|
September 5, 2024
SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer
Jin Li, Yuxian Bai, Zhendong Chen, et al.
Therapeutic Advances in Medical Oncology
|
December 20, 2019
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Shukui Qin, Stephen Lam Chan, Wattana Sukeepaisarnjaroen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2014
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial
Calin Cainap, Shukui Qin, Wen-Tsung Huang, et al.
Page
of 27
Search research articles
Search
Showing results (201-210 of 262) with videos related to
Sort By:
Page
of 27
Journal of Thoracic Disease
|
April 11, 2020
Long-term safety of icotinib in patients with non-small cell lung cancer: a retrospective, real-world study
Wen Zhang, Yiping Zhang, Qiong Zhao, et al.
Cancer Immunology, Immunotherapy : CII
|
January 5, 2022
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial
Jifang Gong, Junning Cao, Qingyuan Zhang, et al.
Journal for Immunotherapy of Cancer
|
June 21, 2020
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
Lin Shen, Jun Guo, Qingyuan Zhang, et al.
Signal Transduction and Targeted Therapy
|
April 26, 2026
Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study
Lin Gui, Haifeng Liu, Huaqing Wang, et al.
Cancer Science
|
August 25, 2019
Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
Xiaoyun Zhou, Jiawei Shou, Jin Sheng, et al.
Advances in Therapy
|
March 2, 2025
First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study
Shukui Qin, Yuxian Bai, Jin Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 8, 2017
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study
Jianming Xu, Tae Won Kim, Lin Shen, et al.
Cancer Immunology, Immunotherapy : CII
|
September 5, 2024
SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer
Jin Li, Yuxian Bai, Zhendong Chen, et al.
Therapeutic Advances in Medical Oncology
|
December 20, 2019
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Shukui Qin, Stephen Lam Chan, Wattana Sukeepaisarnjaroen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2014
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial
Calin Cainap, Shukui Qin, Wen-Tsung Huang, et al.
Page
of 27